Ultime notizie per Synaptogenix (NASDAQ:SNPX) Azioni

Synaptogenix

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Synaptogenix Inc

SNP SCHNEIDER NEUREITHER by SNP Schneider Neureither & Partner AG

SNP Schneider-Neureither & Partner SE

Truist Securities analyst Joseph Civello maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and raises the price target from $310 to $360.

News

Price Target

Analyst Ratings

LULU

Truist Securities Maintains Buy on Lululemon Athletica, Raises Price Target to $360

Truist Securities analyst Terry Tillman reiterates Intapp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) with a Buy and raises the price target from $47 to $55.

Reiteration

INTA

Truist Securities Reiterates Buy on Intapp, Raises Price Target to $55

Texas' battle over high housing prices, escalating in cities like Austin and Dallas, highlights the growing tension between proponents of denser housing options and established single-family neighborhoods.&nbsp;
In Austin, a powerful YIMBY (Yes-In-My-Backyard) movement, born from the skyrocketing housing costs exacerbated by the COVID-19 pandemic, advocates for <a href="https://www.benzinga.com/real-estate/24/09/41082529/its-not-a-housing-crisis-but-a-housing-policy-crisis-homebuilders-call-out-roadblocks-as-prices-surg">housing policies</a> that welcome higher-density homes in traditionally single-family zones.&nbsp;
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
With support from a YIMBY-leaning city council, Austin has passed sweeping reforms to relax zoning, allowing up to three housing units on plots once reserved for single-family homes and significantly reducing lot size requirements. Austin&#8217;s mayor, Kirk Watson, emphasizes that inaction on housing affordability isn't viable, underscoring that the city is changing &#8220;for better or worse.&#8221;
Critics, however, express concerns that allowing high-density developments will push up prices in historically affordable areas, risking further displacement of marginalized communities. Alexia Leclerq, a representative of Community Powered ATX, warns that Austin's recent zoning reforms could intensify this issue, arguing, "We want deeply affordable housing, not policies that make things worse."&nbsp;
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
Research backs YIMBY advocates, suggesting that more homes could relieve pressure on existing neighborhoods. Even before recent zoning changes, a surge in new <a href="https://www.benzinga.com/real-estate/24/07/39770650/america-set-for-50-year-apartment-boom-housing-economist-jay-parsons-says">apartment buildings</a> in Austin had driven down rents, offering some relief for residents.
Meanwhile, Dallas presents a cautionary tale of gridlock. A nascent Dallas YIMBY movement, inspired by Austin's policy gains, faced swift opposition from neighborhood advocates who value stability in single-family neighborhoods. Councilmember Cara Mendelsohn argues that Dallas residents who bought homes expect stability, asserting, "People don't want multifamily units mixed into single-family areas."&nbsp;
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
Dallas YIMBYs, like Hexel Colorado, counter that Dallas must evolve with its population's changing needs, but support from local policymakers has been tepid. Despite endorsement for ForwardDallas — a vision document aimed at diversifying housing types — the city remains wary of endorsing denser developments in established areas.
The issue is rippling across Texas, where the state's once-low-cost housing advantage is slipping. Comptroller Glenn Hegar's warning about Texas' housing trajectory reflects bipartisan unease, with 45% of Texans in favor of reducing lot-size requirements, per a recent poll. Onlookers say that should cities fail to take effective action, the state legislature may intervene.&nbsp;
Republican and Democratic lawmakers see housing policy as an opportunity to reform zoning, albeit for different reasons: Republicans favor the market freedom it promises, while Democrats see potential for reducing segregation and environmental impacts.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Real Estate

Texas' Battle Over High Housing Prices Gains Momentum, With Potential To Reshape The Lone Star State For Decades

Truist Securities analyst Tobey Sommer reiterates Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) with a Hold and raises the price target from $33 to $40.

HSII

Truist Securities Reiterates Hold on Heidrick & Struggles Intl, Raises Price Target to $40

The tiny town of Dixville Notch, New Hampshire, cast its votes for president just after midnight as per longstanding tradition, and the results there were the same as polls and predictions across the nation: The race <a href="https://www.benzinga.com/general/politics/24/11/41730670/prediction-markets-swing-back-to-trump-but-data-analysts-say-its-too-close-to-call">between Kamala Harris and Donald Trump is a tie</a>.
What Happened: Harris and Trump each received three votes in the town just south of the Canadian border. That&#8217;s not much different than Nate Silver&#8216;s final analysis in his Silver Bullet newsletter, which gives Harris a 50.015% chance of victory, with Trump with a 49.648% chance and a 0.337% chance of an Electoral College tie. 
FiveThirtyEight&#8217;s data-driven simulations show Harris winning 50.3% of the tests to Trump&#8217;s 49.5% chance, with a 0.2% chance of a tie. Only The Economist&#8217;s model shows anything other than a coin-toss race: Its model had a 50-50 split yesterday, but in its final run, shows a 56% chance of a Harris victory.
Several political analysis websites made final predictions within the past 24 hours, and they all expect Harris wins as well, though mostly by very tight Electoral College margins. CNalysis predicts Harris winning with 308 electoral votes to Trump&#8217;s 230, and Elections Daily predicts a 292-246 Harris win. The Crystal Ball at the University of Virginia Center for Politics sees a 276-262 Harris win, while Split Ticket has Harris winning with the narrowest possible margin, 270-268. That scenario comes if Harris wins the &#8220;Blue Wall&#8221; states of Michigan, Pennsylvania, and Wisconsin, and Trump wins the remaining swing states of Arizona, Georgia, Nevada, and North Carolina.
Also Read: <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">2024 Election Stakes: Potential Sweeps, Split Outcomes In Congressional, Presidential Races</a>
But as of 9:30 a.m. ET on Election Day, the betting markets do not agree. On Kalshi, where Harris briefly took the lead over the weekend, bettors give Trump a 59% chance of victory, and Polymarket wagerers give Trump a 62% chance. Even PredictIt, where Harris was showing a 54% chance of winning on Monday, now gives Trump a 51% chance. Robinhood&#8216;s presidential market has Trump at 58%.
Why It Matters: The final calls from Silver and FiveThirtyEight show rare late agreement between the two data-crunching sites, since Silver has generally been more bearish on Harris. But both have concluded that the race is essentially a tie.
The agreement in the four election experts&#8217; predictions may give the Trump campaign pause, but even in most of these cases, a shift of a state or two could change the result.
The betting markets have been more favorable to Trump throughout the race, but his late gains on Harris indicate continued doubt among bettors that she can pull off a win.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">Trump Vs. Harris: 2024 Election Deadlocked, Final Emerson Poll Shows One Candidate With Small Edge Among Independents</a></li>
</ul>
Image: Shutterstock

Politics

Trump Holds Edge In Betting Markets On Election Day, While Experts Call Tight Race For Harris

Truist Securities analyst Mark Hughes maintains Frontdoor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) with a Buy and raises the price target from $56 to $58.

FTDR

Truist Securities Maintains Buy on Frontdoor, Raises Price Target to $58

Thomson Reuters Corp&nbsp;(NYSE:&nbsp;TRI) reported fiscal third-quarter 2024 revenue&nbsp;growth of 8% year-on-year to $1.72 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740109/thomson-reuters-reports-third-quarter-2024-results" rel="noreferrer noopener">analyst consensus estimate of $1.71 billion</a>.&nbsp;
The business information services provider&#8217;s adjusted EPS of 80 cents beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate of 77 cents</a>. The stock price climbed after the print.
Organic revenues increased by 7%, driven by 8% growth in recurring revenues (84% of total revenues).&nbsp;
The &#8220;Big 3&#8221; segments (Legal Professionals, Corporates, and Tax &amp; Accounting Professionals) collectively comprised 81% of total revenues and reported organic revenue growth of 9%. Here&#8217;s a breakdown:
<ul>
<li>Legal Professionals&#8217; revenue grew by 8% Y/Y to $745 million</li>
<li>Corporates&#8217; revenue rose 12% Y/Y to $437 million</li>
<li>Tax &amp; Accounting Professionals&#8217; revenue increased by 9% Y/Y to $221 million.</li>
<li>Reuters News revenue grew 10% Y/Y to $199 million</li>
<li>Global Print revenue fell 7% Y/Y to $128 million.</li>
<li>Adjusted EBITDA margin declined 430 bps to 35.3%.&nbsp;</li>
<li>Free cash flow was at $591 million during the quarter with $1.73 billion in cash and equivalents as of September.</li>
</ul>
CEO Steve Hasker highlighted the company&#8217;s commitment to innovation, pointing to increased AI investment in 2024, surpassing $200 million. 
He also emphasized progress in the &#8220;Build, Partner, Buy&#8221; strategy, with recent AI product launches, updates to the CoCounsel GenAI assistant, and strategic acquisitions of Safe Sign Technologies and Materia, which enhance the company&#8217;s GenAI solutions for professional clients.
FY24 Outlook:&nbsp;Thomson Reuters&nbsp;reiterated revenue of $7.27 billion against&nbsp;a&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $7.28 billion</a>.
The company expects its&nbsp;fourth-quarter&nbsp;2024 organic revenue growth to be approximately 5% (<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40109618/thomson-reuters-q2-growth-in-revenue-and-big-3-segments-ceo-confirms-2024-investment-plans-on-track" rel="noreferrer noopener">prior approximately&nbsp;6%</a>)&nbsp;and its adjusted EBITDA margin to be approximately 37% (prior approximately&nbsp;34%).
Thomson Reuters stock gained 15% year-to-date.
Price Action:&nbsp;TRI stock is up 4.84% to $173.01 premarket at last check Tuesday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Thomson Reuters Q3 Earnings: Legal, Corporate Segments Enjoy Revenue Boost As CEO Highlights AI Investment

Truist Securities analyst Bill Chappell maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $160 to $170.

FRPT

Truist Securities Maintains Buy on Freshpet, Raises Price Target to $170

Wells Fargo analyst Elyse Greenspan maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and raises the price target from $116 to $117.

Wells Fargo Maintains Equal-Weight on Prudential Financial, Raises Price Target to $117

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 6.32% on an annualized basis producing an average annual return of 17.2%. Currently, Novo Nordisk has a market capitalization of $482.39 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $5,007.62 today based on a price of $110.14 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730820641_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,000 Today

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) has outperformed the market over the past 10 years by 1.96% on an annualized basis producing an average annual return of 12.85%. Currently, Agilent Technologies has a market capitalization of $39.86 billion. 
Buying $100 In A: If an investor had bought $100 of A stock 10 years ago, it would be worth $335.90 today based on a price of $138.74 for A at the time of writing.
<h3>Agilent Technologies's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730820637_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today

Emerson Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) shares traded higher on Tuesday after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740106/emerson-reports-fourth-quarter-and-full-year-2024-results-provides-initial-2025-outlook" rel="noreferrer noopener">fourth-quarter&nbsp;FY24 results</a>.
Net sales growth of 13% year over year to $4.62 billion, beating the consensus of $4.57 billion. Underlying sales were up 4%, and underlying orders increased by 2% in the quarter. Adjusted EPS improved 15% to $1.48, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the consensus of $1.47</a>.
Sales by Segments: Final Control&nbsp;$1.17 billion&nbsp;(+8%), Measurement &amp; Analytical&nbsp;$1.12 billion&nbsp;(+7%), Discrete Automation&nbsp;$643 million&nbsp;(-3%); Safety &amp; Productivity&nbsp;$352 million&nbsp;(-1%), Control Systems &amp; Software&nbsp;$780 million&nbsp;(+9%), AspenTech&nbsp;$215 million&nbsp;(-13%), and Test &amp; Measurement&nbsp;$360 million.
Adjusted Total Segment EBITA was&nbsp;$1.21 billion&nbsp;compared to&nbsp;$1.05 billion&nbsp;in the prior&nbsp;year&nbsp;quarter, and the margin improved by 70&nbsp;bps to&nbsp;26.2%.
Emerson&#8217;s operating cash flow for the quarter totaled $1.07 billion, compared to $991 million in the prior year, and free cash flow was $905 million (+10% Y/Y). Emerson held cash and equivalents of $8.05 billion as of September-end.
Dividend: Emerson declared a quarterly cash dividend per share of $0.5275 (vs. $0.525 prior quarter), payable on December 10, to stockholders of record on&nbsp;November&nbsp;15, 2024.
Emerson President&nbsp;and Chief Executive Officer&nbsp;Lal Karsanbhai&nbsp;said, &#8220;We have done an exceptional job integrating Test &amp; Measurement with&nbsp;$100 million&nbsp;of synergies realized in the first year, and we remain resolute in our focus on executing at a world-class level, guided by our Emerson Management System. Emerson&#8217;s leading technology, alignment with secular trends and customer focus provide confidence for continued momentum in fiscal 2025.&#8221;
Outlook: For FY25, Emerson Electric expects its net sales growth outlook of 3.5% &#8211; 5.5%, with underlying sales growth of 3% &#8211; 5% and adjusted EPS of $5.85 &#8211;<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener"> $6.05 vs. consensus $5.48</a>.
Emerson expects an operating cash flow of&nbsp;$3.6 billion &#8211; $3.7 billion&nbsp;and an FCF of&nbsp;$3.2 billion &#8211; $3.3 billion&nbsp;for FY25.
For the first quarter, the company projects net sales growth of 2.5% &#8211; 3.5% and adjusted EPS of $1.25&nbsp;&#8211;&nbsp;$1.30&nbsp;vs. consensus of $1.28.
Emerson disclosed plans to boost capital returns to shareholders with a share repurchase program totaling around $2 billion for FY25, including $1 billion expected in the fiscal first quarter.
Acquisition: In a separate release, Emerson proposed acquiring all remaining shares of Aspen Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) for an <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41740121/emerson-announces-key-actions-to-complete-the-portfolio-transformation-to-an-industrial-technology" rel="noreferrer noopener">enterprise value of&nbsp;$15.1 billion</a>.
Emerson&#8217;s proposal of $240 per share offers a 35% premium over AspenTech&#8217;s undisturbed share price of $177.84 on August 6, and an 8% premium above its 52-week high of $221.94 through&nbsp;August 6.
Emerson currently owns approximately&nbsp;57%&nbsp;of AspenTech&#8217;s outstanding shares of common stock. Upon completing the transaction, AspenTech would become Emerson&#8217;s wholly-owned subsidiary.
Emerson anticipates that the proposed transaction, including synergies, will have a neutral effect on its Adjusted EPS in fiscal 2025.
Emerson has also initiated a strategic review of its Safety &amp; Productivity segment, considering options like a cash sale. This segment includes the remaining non-automation businesses in Emerson&#8217;s portfolio.
Investors can gain exposure to the stock via&nbsp;ProShares S&amp;P Kensho Smart Factories ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAKX#NYSE">MAKX</a>) and&nbsp;Gabelli Automation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAST#NYSE">GAST</a>).
Price Action: EMR shares are up 8.6% at $119.25 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41745824" target="_blank" rel="noreferrer noopener">Short Squeeze &#8211; GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook</a></li>
</ul>

Equities

Large Cap

Dividends

Buybacks

Asset Sales

Movers

AZPN

GAST

MAKX

Emerson Electric Gains On Q4 Earnings Beat And FY25 Growth Forecast: Eyes AspenTech Buyout

Pineapple Energy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NYSE">PEGY</a>) short percent of float has risen 2843.09% since its last report. The company recently reported that it has 281 thousand shares sold short, which is 91.53% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Pineapple Energy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730820622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pineapple Energy has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pineapple Energy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Pineapple Energy's peer group average for short interest as a percentage of float is 3.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PEGY

(PEGY) - Analyzing Pineapple Energy's Short Interest

JD.com's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JD#NYSE">JD</a>) short percent of float has fallen 11.24% since its last report. The company recently reported that it has 38.34 million shares sold short, which is 3.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>JD.com Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730820617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for JD.com has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing JD.com's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, JD.com's peer group average for short interest as a percentage of float is 9.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into JD.com's Recent Short Interest

Sunrun's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NYSE">RUN</a>) short percent of float has risen 3.38% since its last report. The company recently reported that it has 46.62 million shares sold short, which is 25.09% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sunrun Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730820612_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sunrun has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Sunrun's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sunrun's peer group average for short interest as a percentage of float is 9.22%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Sunrun?

Truist Securities analyst Joon Lee maintains Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) with a Buy and lowers the price target from $12 to $8.

EDIT

Truist Securities Maintains Buy on Editas Medicine, Lowers Price Target to $8

Wells Fargo analyst Elyse Greenspan maintains MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) with a Overweight and raises the price target from $92 to $93.

Wells Fargo Maintains Overweight on MetLife, Raises Price Target to $93

Truist Securities analyst Michael Ciarmoli maintains BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) with a Hold and raises the price target from $95 to $106.

BWXT

Truist Securities Maintains Hold on BWX Technologies, Raises Price Target to $106

Wells Fargo analyst Elyse Greenspan maintains Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) with a Equal-Weight and raises the price target from $106 to $107.

Wells Fargo Maintains Equal-Weight on Aflac, Raises Price Target to $107

Truist Securities analyst Michael Ciarmoli maintains Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) with a Hold and raises the price target from $15 to $22.5.

ATSG

Truist Securities Maintains Hold on Air Transport Services Gr, Raises Price Target to $22.5

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Synaptogenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/snpx-stock-quote/">SNPX</a>) just reported results for the first quarter of 2024.<ul><li>Synaptogenix reported earnings per share of -41 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/snpx-stock-earnings-synaptogenix-for-q1-of-2024/">SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024

An announcement from Synaptogenix (SNPX) is now available. Synaptogenix, Inc. has extended the term of Dr. Alan J. Tuchman, their CEO, through an a...

Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Synaptogenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/snpx-stock-quote/">SNPX</a>) just reported results for the second quarter of 2024.<ul><li>Synaptogenix reported earnings per share of -$1.18.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/snpx-stock-earnings-synaptogenix-for-q2-of-2024/">SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024

Synaptogenix announces $5M financing

Warning: SNPX is at high risk of performing badly

SNPX

Press Releases

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

Small Cap

Stock Split

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Offerings

Synaptogenix Announces $5.0 Million Financing

Aditxt

Ainos

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

180 Life Sciences

Anitra

Bio-Path Hldgs

Chromocell Therapeutics Corporation Common Stock

Chromocell Therapeutics

Carmell

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mainz Biomed

NuCana

Oncternal Therapeutics, Inc. - Common Stock

Oncternal Therapeutics

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Portage Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Comments

Synaptogenix

Notizie

Ultime notizie per Synaptogenix (NASDAQ:SNPX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO